Analgesics
Antiandrogens
Antihistamines
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
TMPRSS2 inh.
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchMIB-626MIB-626 (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta

 

Oral MIB‐626 (β Nicotinamide Mononucleotide) Safely Raises Blood Nicotinamide Adenine Dinucleotide Levels in Hospitalized Patients With COVID‐19 and Acute Kidney Injury: A Randomized Controlled Trial

Pencina et al., FASEB BioAdvances, doi:10.1096/fba.2025-00014, NCT05038488, Jun 2025
https://c19early.org/pencina.html
Mortality -156% improvement lower risk ← → higher risk Recovery, WHO ordin.. 18% Recovery, mSOFA -50% MIB-626  Pencina et al.  LATE TREATMENT RCT Is late treatment with MIB-626 beneficial for COVID-19? Double-blind RCT 39 patients in the USA Trial underpowered for serious outcomes c19early.org Pencina et al., FASEB BioAdvances, Jun 2025 0 0.5 1 1.5 2+ RR
RCT 42 hospitalized patients with COVID-19 and acute kidney injury (AKI) showing no clinical benefit with MIB-626 (β-nicotinamide mononucleotide) treatment. The study found that 1.0g of MIB-626 twice daily safely and significantly raised blood NAD+ levels, but this did not result in any significant difference in the primary endpoint (serum creatinine). Furthermore, there were no significant differences in secondary endpoints, including other markers of AKI (cystatin C, NGAL, KIM-1), inflammation (CRP, IL-6, TNFa), or overall clinical disease severity.
Standard of Care (SOC) for COVID-19 in the study country, the USA, is very poor with very low average efficacy for approved treatments1. Only expensive, high-profit treatments were approved for early treatment. Low-cost treatments were excluded, reducing the probability of early treatment due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments.
risk of death, 156.0% higher, RR 2.56, p = 1.00, treatment 1 of 25 (4.0%), control 0 of 14 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), day 42.
risk of no recovery, 18.2% lower, RR 0.82, p = 0.71, treatment mean 1.1 (±1.72) n=19, control mean 0.9 (±1.33) n=15, relative WHO 8-point scale improvement, day 14.
risk of no recovery, 50.0% higher, RR 1.50, p = 0.80, treatment mean 0.4 (±2.47) n=14, control mean 0.6 (±1.55) n=14, relative mSOFA improvement, day 14.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Pencina et al., 18 Jun 2025, Double Blind Randomized Controlled Trial, USA, peer-reviewed, mean age 68.4, 16 authors, trial NCT05038488 (history). Contact: sbhasin@bwh.harvard.edu.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org November 2025 USA Russia Sudan Angola Colombia Kenya Mozambique Vietnam Peru Philippines Spain Brazil Italy France Japan Canada China Uzbekistan Nepal Ethiopia Iran Ghana Mexico South Korea Germany Bangladesh Saudi Arabia Algeria Morocco Yemen Poland India DR Congo Madagascar Thailand Uganda Venezuela Nigeria Egypt Bolivia Taiwan Zambia Fiji Bosnia-Herzegovina Ukraine Côte d'Ivoire Bulgaria Greece Slovakia Singapore Iceland New Zealand Czechia Mongolia Israel Trinidad and Tobago Hong Kong North Macedonia Belarus Qatar Panama Serbia CAR USA favored high-profit treatments.The average efficacy of treatments was very low.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org November 2025 USA Russia Sudan Angola Colombia Kenya Mozambique Vietnam Peru Philippines Spain Brazil Italy France Japan Canada China Uzbekistan Nepal Ethiopia Iran Ghana Mexico South Korea Germany Bangladesh Saudi Arabia Algeria Morocco Yemen Poland India DR Congo Madagascar Thailand Uganda Venezuela Nigeria Egypt Bolivia Taiwan Zambia Fiji Ukraine Côte d'Ivoire Eritrea Bulgaria Greece Slovakia Singapore New Zealand Malawi Czechia Mongolia Israel Trinidad and Tobago North Macedonia Belarus Qatar Panama Serbia Syria USA favored high-profit treatments.The average efficacy was very low.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
Abstract: FASEB BioAdvances RESEARCH ARTICLE OPEN ACCESS Oral MIB-­626 (β Nicotinamide Mononucleotide) Safely Raises Blood Nicotinamide Adenine Dinucleotide Levels in Hospitalized Patients With COVID-­19 and Acute Kidney Injury: A Randomized Controlled Trial Karol M. Pencina1 | David E. Leaf 2 | Rodrigo J. Valderrabano1 | Sushrut S. Waikar3 | Tapan S. Mehta4 | Yili Valentine Shang1 | Nancy K. Latham1 | Tejossy John4 | Elena Volpi5 | Dahlene Fusco6 | Yusnie Memish-Beleva1 | Shobana Krishnamurthy2 | Siva Lavu7 | Salma Karmi7 | David J. Livingston7 | Shalender Bhasin1 1Research Program in Men's Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA | 2Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA | 3Department of Medicine, Section of Nephrology, Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA | 4Department of Family and Community Medicine, University of Alabama, Birmingham, Alabama, USA | 5University of Texas Medical Branch, Galveston, Texas, USA | 6Tulane University School of Medicine, New Orleans, Louisiana, USA | 7 Metro International Biotech, Worcester, Massachusetts, USA Correspondence: Shalender Bhasin (sbhasin@bwh.harvard.edu) Received: 16 January 2025 | Revised: 10 March 2025 | Accepted: 31 March 2025 Funding: The trial was funded by Metro International Biotech LLC. Drs. Bhasin and Pencina were partially supported by the Boston Claude D. Pepper Older Americans Independence Center (National Institute on Aging grant 5P30AG31679). Keywords: acute kidney injury | COVID-­19 | NAD augmentation | NAD metabolism | NAD precursor | nicotinamide mononucleotide ABSTRACT Nicotinamide adenine dinucleotide (NAD+) plays an important role in the innate immune response and is depleted during SARS-­ CoV-­2 infection due to increased turnover. It is unknown whether treatment with NAD+ precursors can safely raise NAD+ levels in patients with COVID-­19. To determine whether MIB-­626 (β-­nicotinamide mononucleotide), an NAD+ precursor, can safely increase blood NAD+ levels and attenuate acute kidney injury (AKI) and inflammation in hospitalized patients with COVID-­19, 42 adults, ≥ 18 years, hospitalized with COVID-­19 and AKI, were randomized in a 3:2 ratio to MIB-­626 1.0-­g or placebo tablets twice daily for 14 days. Circulating NAD+ and its metabolites, markers of AKI, inflammation, and disease severity, were assessed. MIB-­626 treatment significantly but gradually raised blood NAD+ levels to a peak between 5 to 14 days (16.0 ± 6.9, 25.5 ± 12.6, and 42.6 ± 25.6 μg/mL at baseline, days 5 and 14) and raised plasma concentrations of NAD+ metabolites 1-­methylnicotinamide, N-­methyl, 2-­pyridone, 4-­carboxamide rapidly to a peak by day 3. Changes in serum creatinine, cystatin-­C, and serum markers of AKI did not differ significantly between groups. Serum CRP, IL-­6, and TNFα and indices of disease severity also did not differ between groups. MIB-­626 treatment of patients with COVID-­19 and AKI safely and substantially raised blood NAD+ and plasma concentrations of NAD+ metabolites. Markers of AKI, inflammation, and disease severity did not differ between groups, likely due to the slow rise in NAD+ levels. Future studies should assess whether a rapid increase in NAD+ by parenteral administration can attenuate disease severity and AKI. Trial..
DOI record: { "DOI": "10.1096/fba.2025-00014", "ISSN": [ "2573-9832", "2573-9832" ], "URL": "http://dx.doi.org/10.1096/fba.2025-00014", "abstract": "<jats:title>ABSTRACT</jats:title>\n <jats:p>\n Nicotinamide adenine dinucleotide (NAD\n <jats:sup>+</jats:sup>\n ) plays an important role in the innate immune response and is depleted during SARS‐CoV‐2 infection due to increased turnover. It is unknown whether treatment with NAD\n <jats:sup>+</jats:sup>\n precursors can safely raise NAD\n <jats:sup>+</jats:sup>\n levels in patients with COVID‐19. To determine whether MIB‐626 (\n <jats:italic>β‐</jats:italic>\n nicotinamide mononucleotide), an NAD\n <jats:sup>+</jats:sup>\n precursor, can safely increase blood NAD\n <jats:sup>+</jats:sup>\n levels and attenuate acute kidney injury (AKI) and inflammation in hospitalized patients with COVID‐19, 42 adults, ≥ 18 years, hospitalized with COVID‐19 and AKI, were randomized in a 3:2 ratio to MIB‐626 1.0‐g or placebo tablets twice daily for 14 days. Circulating NAD\n <jats:sup>+</jats:sup>\n and its metabolites, markers of AKI, inflammation, and disease severity, were assessed. MIB‐626 treatment significantly but gradually raised blood NAD\n <jats:sup>+</jats:sup>\n levels to a peak between 5 to 14 days (16.0 ± 6.9, 25.5 ± 12.6, and 42.6 ± 25.6 μg/mL at baseline, days 5 and 14) and raised plasma concentrations of NAD\n <jats:sup>+</jats:sup>\n metabolites 1‐methylnicotinamide, N‐methyl, 2‐pyridone, 4‐carboxamide rapidly to a peak by day 3. Changes in serum creatinine, cystatin‐C, and serum markers of AKI did not differ significantly between groups. Serum CRP, IL‐6, and TNFα and indices of disease severity also did not differ between groups. MIB‐626 treatment of patients with COVID‐19 and AKI safely and substantially raised blood NAD\n <jats:sup>+</jats:sup>\n and plasma concentrations of NAD\n <jats:sup>+</jats:sup>\n metabolites. Markers of AKI, inflammation, and disease severity did not differ between groups, likely due to the slow rise in NAD\n <jats:sup>+</jats:sup>\n levels. Future studies should assess whether a rapid increase in NAD\n <jats:sup>+</jats:sup>\n by parenteral administration can attenuate disease severity and AKI.\n </jats:p>\n <jats:p>\n <jats:bold>Trial Registration:</jats:bold>\n <jats:ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"http://clinicaltrials.gov\">ClinicalTrials.gov</jats:ext-link>\n Identifier: NCT05038488\n </jats:p>", "alternative-id": [ "10.1096/fba.2025-00014" ], "article-number": "e70011", "assertion": [ { "group": { "label": "Publication History", "name": "publication_history" }, "label": "Received", "name": "received", "order": 0, "value": "2025-01-16" }, { "group": { "label": "Publication History", "name": "publication_history" }, "label": "Accepted", "name": "accepted", "order": 2, "value": "2025-03-31" }, { "group": { "label": "Publication History", "name": "publication_history" }, "label": "Published", "name": "published", "order": 3, "value": "2025-06-18" } ], "author": [ { "affiliation": [ { "name": "Research Program in Men's Health: Aging and Metabolism Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA" } ], "family": "Pencina", "given": "Karol M.", "sequence": "first" }, { "affiliation": [ { "name": "Division of Renal Medicine Brigham and Women's Hospital Boston Massachusetts USA" } ], "family": "Leaf", "given": "David E.", "sequence": "additional" }, { "affiliation": [ { "name": "Research Program in Men's Health: Aging and Metabolism Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA" } ], "family": "Valderrabano", "given": "Rodrigo J.", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Medicine, Section of Nephrology Boston Medical Center and Boston University Chobanian &amp; Avedisian School of Medicine Boston Massachusetts USA" } ], "family": "Waikar", "given": "Sushrut S.", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Family and Community Medicine University of Alabama Birmingham Alabama USA" } ], "family": "Mehta", "given": "Tapan S.", "sequence": "additional" }, { "affiliation": [ { "name": "Research Program in Men's Health: Aging and Metabolism Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA" } ], "family": "Shang", "given": "Yili Valentine", "sequence": "additional" }, { "affiliation": [ { "name": "Research Program in Men's Health: Aging and Metabolism Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA" } ], "family": "Latham", "given": "Nancy K.", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Family and Community Medicine University of Alabama Birmingham Alabama USA" } ], "family": "John", "given": "Tejossy", "sequence": "additional" }, { "affiliation": [ { "name": "University of Texas Medical Branch Galveston Texas USA" } ], "family": "Volpi", "given": "Elena", "sequence": "additional" }, { "affiliation": [ { "name": "Tulane University School of Medicine New Orleans Louisiana USA" } ], "family": "Fusco", "given": "Dahlene", "sequence": "additional" }, { "affiliation": [ { "name": "Research Program in Men's Health: Aging and Metabolism Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA" } ], "family": "Memish‐Beleva", "given": "Yusnie", "sequence": "additional" }, { "affiliation": [ { "name": "Division of Renal Medicine Brigham and Women's Hospital Boston Massachusetts USA" } ], "family": "Krishnamurthy", "given": "Shobana", "sequence": "additional" }, { "affiliation": [ { "name": "Metro International Biotech Worcester Massachusetts USA" } ], "family": "Lavu", "given": "Siva", "sequence": "additional" }, { "affiliation": [ { "name": "Metro International Biotech Worcester Massachusetts USA" } ], "family": "Karmi", "given": "Salma", "sequence": "additional" }, { "affiliation": [ { "name": "Metro International Biotech Worcester Massachusetts USA" } ], "family": "Livingston", "given": "David J.", "sequence": "additional" }, { "ORCID": "https://orcid.org/0000-0002-3982-6200", "affiliation": [ { "name": "Research Program in Men's Health: Aging and Metabolism Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA" } ], "authenticated-orcid": false, "family": "Bhasin", "given": "Shalender", "sequence": "additional" } ], "container-title": "FASEB BioAdvances", "container-title-short": "FASEB BioAdvances", "content-domain": { "crossmark-restriction": true, "domain": [ "faseb.onlinelibrary.wiley.com" ] }, "created": { "date-parts": [ [ 2025, 6, 19 ] ], "date-time": "2025-06-19T00:45:49Z", "timestamp": 1750293949000 }, "deposited": { "date-parts": [ [ 2025, 10, 28 ] ], "date-time": "2025-10-28T15:37:59Z", "timestamp": 1761665879000 }, "indexed": { "date-parts": [ [ 2025, 10, 28 ] ], "date-time": "2025-10-28T15:46:16Z", "timestamp": 1761666376303, "version": "build-2065373602" }, "is-referenced-by-count": 0, "issue": "8", "issued": { "date-parts": [ [ 2025, 6, 18 ] ] }, "journal-issue": { "issue": "8", "published-print": { "date-parts": [ [ 2025, 8 ] ] } }, "language": "en", "license": [ { "URL": "http://creativecommons.org/licenses/by-nc-nd/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2025, 6, 18 ] ], "date-time": "2025-06-18T00:00:00Z", "timestamp": 1750204800000 } } ], "link": [ { "URL": "https://faseb.onlinelibrary.wiley.com/doi/pdf/10.1096/fba.2025-00014", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "311", "original-title": [], "prefix": "10.1096", "published": { "date-parts": [ [ 2025, 6, 18 ] ] }, "published-online": { "date-parts": [ [ 2025, 6, 18 ] ] }, "published-print": { "date-parts": [ [ 2025, 8 ] ] }, "publisher": "Wiley", "reference": [ { "DOI": "10.1016/S0140-6736(20)31189-2", "doi-asserted-by": "publisher", "key": "e_1_2_10_2_1" }, { "DOI": "10.1001/jama.2020.2648", "doi-asserted-by": "publisher", "key": "e_1_2_10_3_1" }, { "DOI": "10.1056/NEJMoa2004500", "doi-asserted-by": "publisher", "key": "e_1_2_10_4_1" }, { "key": "e_1_2_10_5_1", "unstructured": "350(c)(1)(B). USCU “Guidance for Clinical Investigators Sponsors and IRBs—Investigational New Drug Applications (INDs)—Determining Whether Human Research Studies Can Be Conducted Without an IND September 2013 (Final Guidance)”." }, { "DOI": "10.1172/JCI137647", "doi-asserted-by": "publisher", "key": "e_1_2_10_6_1" }, { "DOI": "10.1016/S0140‐6736(20)30628‐0", "doi-asserted-by": "publisher", "key": "e_1_2_10_7_1" }, { "DOI": "10.1093/cid/ciaa248", "doi-asserted-by": "publisher", "key": "e_1_2_10_8_1" }, { "DOI": "10.1038/cmi.2015.74", "doi-asserted-by": "publisher", "key": "e_1_2_10_9_1" }, { "DOI": "10.3389/fimmu.2015.00361", "doi-asserted-by": "publisher", "key": "e_1_2_10_10_1" }, { "DOI": "10.1016/S0140-6736(23)00510-X", "doi-asserted-by": "publisher", "key": "e_1_2_10_11_1" }, { "DOI": "10.1016/S0140-6736(21)00676-0", "doi-asserted-by": "publisher", "key": "e_1_2_10_12_1" }, { "DOI": "10.1001/jama.2021.11330", "doi-asserted-by": "publisher", "key": "e_1_2_10_13_1" }, { "article-title": "Janus Kinase Inhibitors for the Treatment of COVID‐19", "author": "Kramer A.", "issue": "6", "journal-title": "Cochrane Database of Systematic Reviews", "key": "e_1_2_10_14_1", "volume": "6", "year": "2022" }, { "DOI": "10.1016/j.it.2022.02.001", "doi-asserted-by": "publisher", "key": "e_1_2_10_15_1" }, { "DOI": "10.1074/jbc.RA120.015138", "doi-asserted-by": "publisher", "key": "e_1_2_10_16_1" }, { "DOI": "10.1111/acel.14326", "doi-asserted-by": "publisher", "key": "e_1_2_10_17_1" }, { "DOI": "10.1038/ncomms12948", "doi-asserted-by": "publisher", "key": "e_1_2_10_18_1" }, { "DOI": "10.1210/clinem/dgad027", "doi-asserted-by": "publisher", "key": "e_1_2_10_19_1" }, { "DOI": "10.1093/gerona/glac049", "doi-asserted-by": "publisher", "key": "e_1_2_10_20_1" }, { "DOI": "10.1038/s41467-018-03421-7", "doi-asserted-by": "publisher", "key": "e_1_2_10_21_1" }, { "DOI": "10.1371/journal.pone.0186459", "doi-asserted-by": "publisher", "key": "e_1_2_10_22_1" }, { "DOI": "10.1042/BSR20150247", "doi-asserted-by": "publisher", "key": "e_1_2_10_23_1" }, { "DOI": "10.1038/s41598-019-46120-z", "doi-asserted-by": "publisher", "key": "e_1_2_10_24_1" }, { "DOI": "10.1002/hep.32778", "doi-asserted-by": "publisher", "key": "e_1_2_10_25_1" }, { "DOI": "10.1038/s41514-017-0016-9", "doi-asserted-by": "publisher", "key": "e_1_2_10_26_1" }, { "DOI": "10.1093/ajcn/nqy132", "doi-asserted-by": "publisher", "key": "e_1_2_10_27_1" }, { "DOI": "10.1126/science.abe9985", "doi-asserted-by": "publisher", "key": "e_1_2_10_28_1" }, { "DOI": "10.1038/s41598-017-03418-0", "doi-asserted-by": "publisher", "key": "e_1_2_10_29_1" }, { "DOI": "10.1016/j.bbamcr.2013.04.005", "doi-asserted-by": "publisher", "key": "e_1_2_10_30_1" }, { "DOI": "10.3389/fimmu.2023.1158455", "doi-asserted-by": "publisher", "key": "e_1_2_10_31_1" }, { "DOI": "10.1038/s41591-018-0138-z", "doi-asserted-by": "publisher", "key": "e_1_2_10_32_1" }, { "DOI": "10.34067/KID.0006452020", "doi-asserted-by": "publisher", "key": "e_1_2_10_33_1" }, { "article-title": "Nicotinamide Mononucleotide Is Safely Metabolized and Significantly Reduces Blood Triglyceride Levels in Healthy Individuals", "author": "Kimura S.", "issue": "9", "journal-title": "Cureus", "key": "e_1_2_10_34_1", "volume": "14", "year": "2022" }, { "DOI": "10.1002/advs.202101222", "doi-asserted-by": "publisher", "key": "e_1_2_10_35_1" } ], "reference-count": 34, "references-count": 34, "relation": {}, "resource": { "primary": { "URL": "https://faseb.onlinelibrary.wiley.com/doi/10.1096/fba.2025-00014" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Oral\n <scp>MIB</scp>\n ‐626 (β Nicotinamide Mononucleotide) Safely Raises Blood Nicotinamide Adenine Dinucleotide Levels in Hospitalized Patients With\n <scp>COVID</scp>\n ‐19 and Acute Kidney Injury: A Randomized Controlled Trial", "type": "journal-article", "update-policy": "https://doi.org/10.1002/crossmark_policy", "volume": "7" }
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit